{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:48:46Z","timestamp":1790797726288,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T00:00:00Z","timestamp":1478217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000046","name":"Abbott Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s13365-016-0490-z","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T17:03:46Z","timestamp":1478279026000},"page":"216-225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A decreasing CD4\/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication"],"prefix":"10.1007","volume":"23","author":[{"given":"Matteo","family":"Vassallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Durant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lebrun-Frenay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ticchioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"DeSalvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Harvey-Langton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dunais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Laffon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cottalorda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dellamonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pradier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,4]]},"reference":[{"key":"490_CR1","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","volume":"69","author":"A Antinori","year":"2007","unstructured":"Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789\u20131799","journal-title":"Neurology"},{"key":"490_CR2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1126\/science.277.5322.112","volume":"277","author":"B Autran","year":"1997","unstructured":"Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debr\u00e9 P, Leibowitch J (1997) Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112\u2013116","journal-title":"Science"},{"key":"490_CR3","doi-asserted-by":"publisher","unstructured":"Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simspon DM, Ellis RJ, Atkinson JH, Grant I, Heaton RK for the CHARTER Group (2012) Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol 26. doi: 10.1080\/13854046.2012.694479","DOI":"10.1080\/13854046.2012.694479"},{"key":"490_CR4","doi-asserted-by":"crossref","unstructured":"Caby F, Guihot A, Lambert-Niclot S, Guiguet M, Boutolleau D, Agher R, Valantin MA, Tubiana R, Calvez V, Marcelin AG, Carcelain G, Autran B, Costagliola D, Katlama C (2016) Determinants of a low CD4\/Cd8 ratio in HIV-1-infected individuals despite long-term viral suppression. Clin Infect Dis","DOI":"10.1093\/cid\/ciw076"},{"key":"490_CR5","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1086\/340521","volume":"185","author":"TW Chun","year":"2002","unstructured":"Chun TW, Justement JS, Pandya P, Hallahan CW, McLaughlin M, Liu S, Ehler LA, Kovacs C, Fauci AS (2002) Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis 185:1672\u20131676","journal-title":"J Infect Dis"},{"key":"490_CR6","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1182\/blood-2009-02-204172","volume":"113","author":"GM Clifford","year":"2009","unstructured":"Clifford GM, Rickenbach M, Lise M, Dal Maso L, Battegay M, Bohlius J, Boffi El Amari E, Karrer U, Jundt G, Bordoni A, Ess S, Franceschi S, Swiss HIV Cohort Study (2009) Hodgkin lymphoma in the Swiss HIV cohort study. Blood 113:5737\u20135742","journal-title":"Blood"},{"key":"490_CR7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1212\/WNL.0b013e3181ab2b3b","volume":"73","author":"LA Cysique","year":"2009","unstructured":"Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, McCutchan JA, Heaton RK, Ellis RJ (2009) Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapies. Neurology 73:342\u2013348","journal-title":"Neurology"},{"key":"490_CR8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-med-042909-093756","volume":"62","author":"Deeks","year":"2011","unstructured":"Deeks (2011) HIV infection, inflammation, immunosenescence, and aging. Ann Med 62:141\u2013155","journal-title":"Ann Med"},{"key":"490_CR9","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/cid\/cir936","volume":"54","author":"T Doyle","year":"2012","unstructured":"Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, Phillips AN, Geretti AM (2012) Plasma HIV-1 RNA detection below 50 copies\/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis 54:724\u2013732","journal-title":"Clin Infect Dis"},{"key":"490_CR10","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1097\/QAD.0b013e32834a40cd","volume":"25","author":"RJ Ellis","year":"2011","unstructured":"Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S, McCutchan JA, Grant I; CHARTER Group (2011) CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25:1747\u20131751","journal-title":"AIDS"},{"key":"490_CR11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/cid\/cit921","volume":"58","author":"RJ Ellis","year":"2014","unstructured":"Ellis RJ, Letendre S, Vaida F, Haubrich R, Heaton RK, Sacktor N, Clifford DB, Best BM, May S, Umlauf A, Cherner M, Sanders C, Ballard C, Simpson DM, Jay C, McCutchan JA (2014) Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorders. Clin Infect Dis 58:1015\u20131022","journal-title":"Clin Infect Dis"},{"key":"490_CR12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fimmu.2013.00271","volume":"4","author":"T Fulop","year":"2013","unstructured":"Fulop T, Larbi A, Pawelec G (2013) Human T cell aging and the impact of persistent viral infections. Front Immuno 4:271","journal-title":"Front Immuno"},{"key":"490_CR13","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/cid\/cir933","volume":"54","author":"RT Gandhi","year":"2012","unstructured":"Gandhi RT, Deeks SG (2012) Plasma HIV-1 RNA levels during antiretroviral therapy: how low is low enough? Clin Infect Dis 54:733\u2013738","journal-title":"Clin Infect Dis"},{"key":"490_CR14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/COH.0000000000000111","volume":"9","author":"HE Gendelman","year":"2014","unstructured":"Gendelman HE, Gelbard HA (2014) Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders. Curr Opin HIV AIDS 9:585\u2013590","journal-title":"Curr Opin HIV AIDS"},{"key":"490_CR15","doi-asserted-by":"crossref","DOI":"10.1128\/9781555815691","volume-title":"The spectrum of NeuroAIDS disorders","author":"K Goodkin","year":"2009","unstructured":"Goodkin K, Aronow A, Baldwin G et al (2009) The spectrum of NeuroAIDS disorders. ASM press, Washington DC"},{"key":"490_CR16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/acn3.227","volume":"2","author":"OM Grauer","year":"2015","unstructured":"Grauer OM, Reichelt D, Gr\u00fcneberg U, Lohmann H, Schneider-Hohendorf T, Schulte-Mecklenbeck A, Gross CC, Meuth SG, Wiendl H, Husstedt IW (2015) Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid. Ann Clin Transl Neurol 2:906\u2013919","journal-title":"Ann Clin Transl Neurol"},{"key":"490_CR17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1089\/aid.1998.14.561","volume":"14","author":"CM Gray","year":"1998","unstructured":"Gray CM, Schapiro JM, Winters MA, Merigan TC (1998) Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retrovir 14:561\u2013569","journal-title":"AIDS Res Hum Retrovir"},{"key":"490_CR18","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/135965350901400311","volume":"14","author":"M Guiguet","year":"2009","unstructured":"Guiguet M, Kendjo E, Carcelain G, Abgrall S, Mary-Krause M, Tattevin P, Yazdanpanah Y, Costagliola D, Duval X, FHDH-ANRS CO4 Epidemiology Group (2009) CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells\/mm3. Antivir Ther 14:451\u2013457","journal-title":"Antivir Ther"},{"key":"490_CR19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jama.2014.8722","volume":"312","author":"HF G\u00fcnthard","year":"2014","unstructured":"G\u00fcnthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA, International Antiviral Society-USA Panel (2014) Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society\u2014USA panel. JAMA 312:410\u2013425","journal-title":"JAMA"},{"key":"490_CR20","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1212\/WNL.0b013e318200d727","volume":"75","author":"RK Heaton","year":"2010","unstructured":"Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 75:2087\u20132096","journal-title":"Neurology"},{"key":"490_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13365-010-0006-1","volume":"17","author":"RK Heaton","year":"2011","unstructured":"Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Mindt MR, Taylor MJ, Marcotte TD, Atkinson JH, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group, HNRC Group (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:3\u201316","journal-title":"J Neurovirol"},{"key":"490_CR22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/cid\/ciu862","volume":"60","author":"RK Heaton","year":"2015","unstructured":"Heaton RK, Franklin DR Jr, Deutsch R, Letendre S, Ellis RJ, Casaletto K, Marquine MJ, Woods SP, Vaida F, Atkinson JH, Marcotte TD, McCutchan JA, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor N, Morgello S, Simpson DM, Abramson I, Gamst AC, Fennema-Notestine C, Smith DM, Grant I, CHARTER Group (2015) Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis 60:473\u2013480","journal-title":"Clin Infect Dis"},{"key":"490_CR23","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/QAD.0b013e3283601bad","volume":"27","author":"R Karim","year":"2013","unstructured":"Karim R, Mack WJ, Stiller T, Operskalski E, Frederick T, Landay A, Young MA, Tien PC, Augenbraun M, Strickler HD, Kovacs A (2013) Association of HIV clinical disease progression with profiles of early immune activation: results from a cluster analysis approach. AIDS 27:1473\u20131481","journal-title":"AIDS"},{"key":"490_CR24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archneurol.2007.31","volume":"65","author":"S Letendre","year":"2008","unstructured":"Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ, CHARTER Group (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65\u201370","journal-title":"Arch Neurol"},{"key":"490_CR25","unstructured":"Letendre S, McClernon D, Ellis R, Munoz-Moreno J, Way L, Franklin D, Heaton R, Grant I and the CHARTER Group (2009) Persistent HIV in the central nervous system during treatment is associated with worse ART penetration and cognitive impairment (Abstract 484b). 16th Conference on Retrovirus and Opportunistic Infections (CROI). Montreal, Canada"},{"key":"490_CR26","first-page":"190","volume":"65","author":"MJ Marquine","year":"2014","unstructured":"Marquine MJ, Umlauf A, Rooney AS, Fazeli PL, Gouaux BD, Paul Woods S, Letendre SL, Ellis RJ, Grant I, Moore DJ, HIV Neurobehavioral Research Program (HNRP) Group (2014) The veteran aging cohort study index is associated with concurrent risk for neurocognitive impairment. JAIDS 65:190\u2013197","journal-title":"JAIDS"},{"key":"490_CR27","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/QAD.0b013e32832c4152","volume":"23","author":"CM Marra","year":"2009","unstructured":"Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K, AIDS Clinical Trials Group 736 Study Team (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359\u20131366","journal-title":"AIDS"},{"key":"490_CR28","first-page":"175","volume":"2","author":"D Mathez","year":"1997","unstructured":"Mathez D, Bagnarelli P, Gorin I, Katlama C, Pialoux G, Saimot G, Tubiana P, De Truchis P, Chauvin JP, Mills R, Rode R, Clementi M, Leibowitch J (1997) Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Antivir Ther 2:175\u2013183","journal-title":"Antivir Ther"},{"key":"490_CR29","doi-asserted-by":"publisher","unstructured":"Mc Arthur JC, Steiner J, Sacktor N, Nath A (2010) Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 67:699\u2013714. doi: 10.1002\/ana.22053","DOI":"10.1002\/ana.22053"},{"key":"490_CR30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1212\/WNL.0b013e3182478d64","volume":"78","author":"JA McCutchan","year":"2012","unstructured":"McCutchan JA, Marquie-Beck JA, Fitzsimons CA, Letendre SL, Ellis RJ, Heaton RK, Wolfson T, Rosario D, Alexander TJ, Marra C, Ances BM, Grant I, CHARTER Group (2012) Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology 78:485\u2013492","journal-title":"Neurology"},{"key":"490_CR31","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1073\/pnas.86.7.2336","volume":"86","author":"L Osborn","year":"1989","unstructured":"Osborn L, Kundel S, Nabel GJ (1989) Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor KB. Proc Natl Acad Sci U S A 86:2236\u20132340","journal-title":"Proc Natl Acad Sci U S A"},{"key":"490_CR32","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/135965350601100605","volume":"11","author":"HJ Ribaudo","year":"2006","unstructured":"Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM (2006) Design issues in initial HIV-treatment trials: focus on ACTG A5095. Antivir Ther 11:751\u2013760","journal-title":"Antivir Ther"},{"key":"490_CR33","unstructured":"Ribaudo H, Lennox J, Currier J, Kuritzkes D, Gulick R, Haubrich R, Riddler S, Hughes M (2009) Virologic failure endpoint definition in critical trials: is using HIV-RNA threshold <200 copies\/ml better than <50 copies\/ml? An analysis of ACTG studies (abstract 580). 16th Conference on Retrovirus and Opportunistic Infections (CROI). Montreal, Canada"},{"key":"490_CR34","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1097\/QAD.0b013e32828e4e27","volume":"21","author":"KR Robertson","year":"2007","unstructured":"Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21:1915\u20131921","journal-title":"AIDS"},{"key":"490_CR35","first-page":"52","volume":"69","author":"BJ Rudy","year":"2015","unstructured":"Rudy BJ, Kapogiannis BG, Worrell C, Squires K, Bethel J, Li S, Wilson CM, Agwu A, Emmanuel P, Price G, Hudey S, Goodenow MM, Sleasman JW, Adolescent Trials Network for HIVAIDS Interventions (2015) Immune reconstitution but persistent activation after 48\u00a0weeks of antiretroviral therapy in youth with pre-therapy CD4\u00a0<\u00a0350 in ATN 061. J AIDS 69:52\u201360","journal-title":"J AIDS"},{"key":"490_CR36","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/ciu020","volume":"58","author":"MM Santoro","year":"2014","unstructured":"Santoro MM, Fabeni L, Armenia D, Alteri C, Di Pinto D, Forbici F, Bertoli A, Di Carlo D, Gori C, Carta S, Fedele V, D\u2019Arrigo R, Berno G, Ammassari A, Pinnetti C, Nicastri E, Latini A, Tommasi C, Boumis E, Petrosillo N, D\u2019Offizi G, Andreoni M, Ceccherini-Silberstein F, Antinori A, Perno CF (2014) Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis 58:1156\u20131164","journal-title":"Clin Infect Dis"},{"key":"490_CR37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jinf.2012.09.013","volume":"66","author":"S Serrano-Villar","year":"2013","unstructured":"Serrano-Villar S, Guti\u00e9rrez C, Vallejo A, Hern\u00e1ndez-Novoa B, D\u00edaz L, Abad Fern\u00e1ndez M, Madrid N, Dronda F, Zamora J, Mu\u00f1oz-Fern\u00e1ndez M\u00c1, Moreno S (2013a) The CD4\/CD8 ratio in HIV infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect 66:57\u201366","journal-title":"J Infect"},{"key":"490_CR38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/hiv.12081","volume":"15","author":"S Serrano-Villar","year":"2013","unstructured":"Serrano-Villar S, Guti\u00e9rrez C, Vallejo A, Hern\u00e1ndez-Novoa B, D\u00edaz L, Abad Fern\u00e1ndez M, Madrid N, Dronda F, Zamora J, Mu\u00f1oz-Fern\u00e1ndez M\u00c1, Moreno S (2013b) The CD4:CD8 ratio is associated with markers of age-associated disease in virally suppressed HIV-infected patients with immunological recovery. HIV Med 15:40\u201349","journal-title":"HIV Med"},{"issue":"1","key":"490_CR39","doi-asserted-by":"crossref","first-page":"e85798","DOI":"10.1371\/journal.pone.0085798","volume":"9","author":"S Serrano-Villar","year":"2014","unstructured":"Serrano-Villar S, P\u00e9rez-El\u00edas MJ, Dronda F, Casado JL, Moreno A, Royuela A, P\u00e9rez-Molina JA, Sainz T, Navas E, Hermida JM, Quereda C, Moreno S (2014) Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4\/CD8 ratio. PLoS One 9(1):e85798","journal-title":"PLoS One"},{"key":"490_CR40","first-page":"670","volume":"6","author":"J Tang","year":"2015","unstructured":"Tang J, Li X, Price MA, Sanders EJ, Anzala O, Karita E, Kamali A, Lakhi S, Allen S, Hunter E, Kaslow RA, Gilmour J (2015) CD4:CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV-1 infection: findings from an African cohort with prospective data. Front Microbiol 6:670","journal-title":"Front Microbiol"},{"key":"490_CR41","doi-asserted-by":"crossref","first-page":"e97011","DOI":"10.1371\/journal.pone.0097011","volume":"9","author":"W Tinago","year":"2014","unstructured":"Tinago W, Coghlan E, Macken A, McAndrews J, Doak B, Prior-Fuller C, Lambert JS, Sheehan GJ, Mallon PW (2014) Clinical, immunological and treatment-related factors associated with normalized CD4+\/CD8+ T-cell ratio: effect of na\u00efve and memory T-cell subsets. PLoS One 9:e97011","journal-title":"PLoS One"},{"key":"490_CR42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/13550280590952790","volume":"11","author":"V Tozzi","year":"2005","unstructured":"Tozzi V, Balestra P, Lorenzini P, Bellagamba R, Galgani S, Corpolongo A, Vlassi C, Larussa D, Zaccarelli M, Noto P, Visco-Comandini U, Giulianelli M, Ippolito G, Antinori A, Narciso P (2005) Prevalence and risk factors for HIV-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol 11:265\u2013273","journal-title":"J Neurovirol"},{"key":"490_CR43","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s13365-013-0181-y","volume":"19","author":"M Vassallo","year":"2013","unstructured":"Vassallo M, Dunais B, Durant J, Carsenti-Dellamonica H, Harvey-Langton A, Cottalorda J, Ticchioni M, Laffon M, Lebrun-Frenay C, Dellamonica P, Pradier C (2013) Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study. J Neurovir 19:376\u2013382","journal-title":"J Neurovir"},{"key":"490_CR44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/QAD.0000000000000096","volume":"28","author":"M Vassallo","year":"2014","unstructured":"Vassallo M, Durant J, Biscay V, Lebrun-Frenay C, Dunais B, Laffon M, Harvey-Langton A, Cottalorda J, Ticchioni M, Carsenti H, Pradier C, Dellamonica P (2014) Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? AIDS 28:493\u2013501","journal-title":"AIDS"},{"key":"490_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12246","author":"M Vassallo","year":"2015","unstructured":"Vassallo M, Durant J, Lebrun-Frenay C, Fabre R, Ticchioni M, Andersen S, DeSalvador F, Harvey-Langton A, Dunais B, Cohen-Codar I, Montagne N, Cua E, Fredouille-Heripret L, Laffon M, Cottalorda J, Dellamonica P, Pradier C (2015) Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation. HIV Med. doi: 10.1111\/hiv.12246","journal-title":"HIV Med"},{"key":"490_CR46","unstructured":"Vassallo M, Fabre R, Durant J, Lebrun-Frenay C, Dunais B, Laffon M, DeSalvador F, Cottalorda J, Ticchioni M, Dellamonica P, Pradier C (2016) CD4\/CD8 ratio decline and risk of neurocognitive deterioration. 23rd Conference on Retrovirals and Opportunistic Infections (CROI), Boston, February 2016, poster number 408"},{"key":"490_CR47","first-page":"1","volume":"13","author":"I Williams","year":"2012","unstructured":"Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson M, Khoo S, Leen C, Marshall N, Nelson M, Orkin C, Paton N, Phillips A, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski A, Walsh J, Waters L, Wilkins E, Winston A, Youle M (2012) British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 13:1\u201385","journal-title":"HIV Med"},{"key":"490_CR48","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ana.410370315","volume":"37","author":"SG Wilt","year":"1995","unstructured":"Wilt SG, Milward E, Zhou JM, Nagasato K, Patton H, Rusten R, Griffin DE, O\u2019Connor M, Dubois-Dalcq M (1995) In vitro evidence for a dual role of tumor necrosis factor-alfa in human immunodeficiency virus type 1 encephalopathy. Ann Neurol 37:381\u2013394","journal-title":"Ann Neurol"},{"key":"490_CR49","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11065-009-9102-5","volume":"19","author":"SP Woods","year":"2009","unstructured":"Woods SP, Moore DJ, Weber E, Grant I (2009) Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 19:152\u2013168","journal-title":"Neuropsychol Rev"},{"key":"490_CR50","first-page":"168","volume":"47","author":"A Yilmaz","year":"2008","unstructured":"Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gissl\u00e9n M (2008) Persistent intrathecal immune activation in HIV-1 infected individuals with antiretroviral therapy. JAIDS 47:168\u2013173","journal-title":"JAIDS"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-016-0490-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-016-0490-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-016-0490-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T14:43:36Z","timestamp":1657637016000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-016-0490-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,4]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["490"],"URL":"https:\/\/doi.org\/10.1007\/s13365-016-0490-z","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,4]]}}}